-----------------------------
OMB APPROVAL
-----------------------------
OMB Number: 3235-0145
Expires: August 31, 1999
Estimated average burden
hours per response . . .14.90
-----------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ________ )*
InKine Pharmaceutical Company, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.0001 par value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
457214 10 4
-----------------------
(CUSIP Number)
December 31, 1998
- --------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SEC 1745 (3-98)
Page 1 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 2 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
|--------|---------------------------------------------------------------------|
| 1 | NAMES OF REPORTING PERSONS |
| | I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
| | |
| | Oxford Bioscience Partners II, L.P. |
|--------|---------------------------------------------------------------------|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
| | (SEE INSTRUCTIONS) (a) [ ] |
| | (b) [ ] |
|--------|---------------------------------------------------------------------|
| 3 | SEC USE ONLY |
| | |
|--------|---------------------------------------------------------------------|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |
| | |
| | Delaware Limited Partnership |
|-----------------|--------|---------------------------------------------------|
| | 5 | SOLE VOTING POWER |
| | | 0 Shares |
| NUMBER OF |--------|---------------------------------------------------|
| SHARES | 6 | SHARED VOTING POWER |
| BENEFICIALLY | | 1,750,000 Shares |
| OWNED BY |--------|---------------------------------------------------|
| EACH | 7 | SOLE DISPOSITIVE POWER |
| REPORTING | | 0 Shares |
| PERSON |--------|---------------------------------------------------|
| WITH: | 8 | SHARED DISPOSITIVE POWER |
| | | 1,750,000 Shares |
|------------------------------------------------------------------------------|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| | |
| | 1,750,000 Shares |
|--------|---------------------------------------------------------------------|
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN |
| | SHARES (SEE INSTRUCTIONS) |
| | [ ] |
|--------|---------------------------------------------------------------------|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
| | 7.7% |
|--------|---------------------------------------------------------------------|
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
| | PN |
- --------------------------------------------------------------------------------
Page 2 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 3 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
|--------|---------------------------------------------------------------------|
| 1 | NAMES OF REPORTING PERSONS |
| | I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
| | |
| | Oxford Bioscience Partners (Adjunct) II, L.P. |
|--------|---------------------------------------------------------------------|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
| | (SEE INSTRUCTIONS) (a) [ ] |
| | (b) [ ] |
|--------|---------------------------------------------------------------------|
| 3 | SEC USE ONLY |
| | |
|--------|---------------------------------------------------------------------|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |
| | |
| | Delaware Limited Partnership |
|-----------------|--------|---------------------------------------------------|
| | 5 | SOLE VOTING POWER |
| | | 0 Shares |
| NUMBER OF |--------|---------------------------------------------------|
| SHARES | 6 | SHARED VOTING POWER |
| BENEFICIALLY | | 1,750,000 Shares |
| OWNED BY |--------|---------------------------------------------------|
| EACH | 7 | SOLE DISPOSITIVE POWER |
| REPORTING | | 0 Shares |
| PERSON |--------|---------------------------------------------------|
| WITH: | 8 | SHARED DISPOSITIVE POWER |
| | | 1,750,000 Shares |
|------------------------------------------------------------------------------|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| | |
| | 1,750,000 Shares |
|--------|---------------------------------------------------------------------|
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN |
| | SHARES (SEE INSTRUCTIONS) |
| | [ ] |
|--------|---------------------------------------------------------------------|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
| | 7.7% |
|--------|---------------------------------------------------------------------|
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
| | PN |
- --------------------------------------------------------------------------------
Page 3 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 4 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
|--------|---------------------------------------------------------------------|
| 1 | NAMES OF REPORTING PERSONS |
| | I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
| | |
| | Oxford Bioscience Partners (GS-Adjunct) II, L.P. |
|--------|---------------------------------------------------------------------|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
| | (SEE INSTRUCTIONS) (a) [ ] |
| | (b) [ ] |
|--------|---------------------------------------------------------------------|
| 3 | SEC USE ONLY |
| | |
|--------|---------------------------------------------------------------------|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |
| | |
| | Delaware Limited Partnership |
|-----------------|--------|---------------------------------------------------|
| | 5 | SOLE VOTING POWER |
| | | 0 Shares |
| NUMBER OF |--------|---------------------------------------------------|
| SHARES | 6 | SHARED VOTING POWER |
| BENEFICIALLY | | 1,750,000 Shares |
| OWNED BY |--------|---------------------------------------------------|
| EACH | 7 | SOLE DISPOSITIVE POWER |
| REPORTING | | 0 Shares |
| PERSON |--------|---------------------------------------------------|
| WITH: | 8 | SHARED DISPOSITIVE POWER |
| | | 1,750,000 Shares |
|------------------------------------------------------------------------------|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| | |
| | 1,750,000 Shares |
|--------|---------------------------------------------------------------------|
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN |
| | SHARES (SEE INSTRUCTIONS) |
| | [ ] |
|--------|---------------------------------------------------------------------|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
| | 7.7% |
|--------|---------------------------------------------------------------------|
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
| | PN |
- --------------------------------------------------------------------------------
Page 4 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 5 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
|--------|---------------------------------------------------------------------|
| 1 | NAMES OF REPORTING PERSONS |
| | I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
| | |
| | OBP Management II, L.P. |
|--------|---------------------------------------------------------------------|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
| | (SEE INSTRUCTIONS) (a) [ ] |
| | (b) [ ] |
|--------|---------------------------------------------------------------------|
| 3 | SEC USE ONLY |
| | |
|--------|---------------------------------------------------------------------|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |
| | |
| | Delaware Limited Partnership |
|-----------------|--------|---------------------------------------------------|
| | 5 | SOLE VOTING POWER |
| | | 0 Shares |
| NUMBER OF |--------|---------------------------------------------------|
| SHARES | 6 | SHARED VOTING POWER |
| BENEFICIALLY | | 1,750,000 Shares |
| OWNED BY |--------|---------------------------------------------------|
| EACH | 7 | SOLE DISPOSITIVE POWER |
| REPORTING | | 0 Shares |
| PERSON |--------|---------------------------------------------------|
| WITH: | 8 | SHARED DISPOSITIVE POWER |
| | | 1,750,000 Shares |
|------------------------------------------------------------------------------|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| | |
| | 1,750,000 Shares |
|--------|---------------------------------------------------------------------|
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN |
| | SHARES (SEE INSTRUCTIONS) |
| | [ ] |
|--------|---------------------------------------------------------------------|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
| | 7.7% |
|--------|---------------------------------------------------------------------|
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
| | PN |
- --------------------------------------------------------------------------------
Page 5 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 6 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
|--------|---------------------------------------------------------------------|
| 1 | NAMES OF REPORTING PERSONS |
| | I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
| | |
| | Oxford Bioscience Partners (Bermuda) II, Limited Partnership |
|--------|---------------------------------------------------------------------|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
| | (SEE INSTRUCTIONS) (a) [ ] |
| | (b) [ ] |
|--------|---------------------------------------------------------------------|
| 3 | SEC USE ONLY |
| | |
|--------|---------------------------------------------------------------------|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |
| | |
| | Bermuda Limited Partnership |
|-----------------|--------|---------------------------------------------------|
| | 5 | SOLE VOTING POWER |
| | | 0 Shares |
| NUMBER OF |--------|---------------------------------------------------|
| SHARES | 6 | SHARED VOTING POWER |
| BENEFICIALLY | | 1,750,000 Shares |
| OWNED BY |--------|---------------------------------------------------|
| EACH | 7 | SOLE DISPOSITIVE POWER |
| REPORTING | | 0 Shares |
| PERSON |--------|---------------------------------------------------|
| WITH: | 8 | SHARED DISPOSITIVE POWER |
| | | 1,750,000 Shares |
|------------------------------------------------------------------------------|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| | |
| | 1,750,000 Shares |
|--------|---------------------------------------------------------------------|
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN |
| | SHARES (SEE INSTRUCTIONS) |
| | [ ] |
|--------|---------------------------------------------------------------------|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
| | 7.7% |
|--------|---------------------------------------------------------------------|
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
| | PN |
- --------------------------------------------------------------------------------
Page 6 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 7 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
|--------|---------------------------------------------------------------------|
| 1 | NAMES OF REPORTING PERSONS |
| | I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
| | |
| | OBP Management (Bermuda) II Limited Partnership |
|--------|---------------------------------------------------------------------|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
| | (SEE INSTRUCTIONS) (a) [ ] |
| | (b) [ ] |
|--------|---------------------------------------------------------------------|
| 3 | SEC USE ONLY |
| | |
|--------|---------------------------------------------------------------------|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |
| | |
| | Bermuda Limited Partnership |
|-----------------|--------|---------------------------------------------------|
| | 5 | SOLE VOTING POWER |
| | | 0 Shares |
| NUMBER OF |--------|---------------------------------------------------|
| SHARES | 6 | SHARED VOTING POWER |
| BENEFICIALLY | | 1,750,000 Shares |
| OWNED BY |--------|---------------------------------------------------|
| EACH | 7 | SOLE DISPOSITIVE POWER |
| REPORTING | | 0 Shares |
| PERSON |--------|---------------------------------------------------|
| WITH: | 8 | SHARED DISPOSITIVE POWER |
| | | 1,750,000 Shares |
|------------------------------------------------------------------------------|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| | |
| | 1,750,000 Shares |
|--------|---------------------------------------------------------------------|
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN |
| | SHARES (SEE INSTRUCTIONS) |
| | [ ] |
|--------|---------------------------------------------------------------------|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
| | 7.7% |
|--------|---------------------------------------------------------------------|
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
| | PN |
- --------------------------------------------------------------------------------
Page 7 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 8 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
|--------|---------------------------------------------------------------------|
| 1 | NAMES OF REPORTING PERSONS |
| | I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
| | |
| | OBP Management (Bermuda) II Ltd. |
|--------|---------------------------------------------------------------------|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
| | (SEE INSTRUCTIONS) (a) [ ] |
| | (b) [ ] |
|--------|---------------------------------------------------------------------|
| 3 | SEC USE ONLY |
| | |
|--------|---------------------------------------------------------------------|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |
| | |
| | Bermuda Company |
|-----------------|--------|---------------------------------------------------|
| | 5 | SOLE VOTING POWER |
| | | 0 Shares |
| NUMBER OF |--------|---------------------------------------------------|
| SHARES | 6 | SHARED VOTING POWER |
| BENEFICIALLY | | 1,750,000 Shares |
| OWNED BY |--------|---------------------------------------------------|
| EACH | 7 | SOLE DISPOSITIVE POWER |
| REPORTING | | 0 Shares |
| PERSON |--------|---------------------------------------------------|
| WITH: | 8 | SHARED DISPOSITIVE POWER |
| | | 1,750,000 Shares |
|------------------------------------------------------------------------------|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| | |
| | 1,750,000 Shares |
|--------|---------------------------------------------------------------------|
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN |
| | SHARES (SEE INSTRUCTIONS) |
| | [ ] |
|--------|---------------------------------------------------------------------|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
| | 7.7% |
|--------|---------------------------------------------------------------------|
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
| | CO |
- --------------------------------------------------------------------------------
Page 8 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 9 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
|--------|---------------------------------------------------------------------|
| 1 | NAMES OF REPORTING PERSONS |
| | I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
| | |
| | Edmund M. Olivier |
|--------|---------------------------------------------------------------------|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
| | (SEE INSTRUCTIONS) (a) [ ] |
| | (b) [ ] |
|--------|---------------------------------------------------------------------|
| 3 | SEC USE ONLY |
| | |
|--------|---------------------------------------------------------------------|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |
| | |
| | United States |
|-----------------|--------|---------------------------------------------------|
| | 5 | SOLE VOTING POWER |
| | | 0 Shares |
| NUMBER OF |--------|---------------------------------------------------|
| SHARES | 6 | SHARED VOTING POWER |
| BENEFICIALLY | | 1,750,000 Shares |
| OWNED BY |--------|---------------------------------------------------|
| EACH | 7 | SOLE DISPOSITIVE POWER |
| REPORTING | | 0 Shares |
| PERSON |--------|---------------------------------------------------|
| WITH: | 8 | SHARED DISPOSITIVE POWER |
| | | 1,750,000 Shares |
|------------------------------------------------------------------------------|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| | |
| | 1,750,000 Shares |
|--------|---------------------------------------------------------------------|
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN |
| | SHARES (SEE INSTRUCTIONS) |
| | [ ] |
|--------|---------------------------------------------------------------------|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
| | 7.7% |
|--------|---------------------------------------------------------------------|
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
| | IN |
- --------------------------------------------------------------------------------
Page 9 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 10 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
|--------|---------------------------------------------------------------------|
| 1 | NAMES OF REPORTING PERSONS |
| | I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
| | |
| | Cornelius T. Ryan |
|--------|---------------------------------------------------------------------|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
| | (SEE INSTRUCTIONS) (a) [ ] |
| | (b) [ ] |
|--------|---------------------------------------------------------------------|
| 3 | SEC USE ONLY |
| | |
|--------|---------------------------------------------------------------------|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |
| | |
| | United States |
|-----------------|--------|---------------------------------------------------|
| | 5 | SOLE VOTING POWER |
| | | 0 Shares |
| NUMBER OF |--------|---------------------------------------------------|
| SHARES | 6 | SHARED VOTING POWER |
| BENEFICIALLY | | 1,750,000 Shares |
| OWNED BY |--------|---------------------------------------------------|
| EACH | 7 | SOLE DISPOSITIVE POWER |
| REPORTING | | 0 Shares |
| PERSON |--------|---------------------------------------------------|
| WITH: | 8 | SHARED DISPOSITIVE POWER |
| | | 1,750,000 Shares |
|------------------------------------------------------------------------------|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| | |
| | 1,750,000 Shares |
|--------|---------------------------------------------------------------------|
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN |
| | SHARES (SEE INSTRUCTIONS) |
| | [ ] |
|--------|---------------------------------------------------------------------|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
| | 7.7% |
|--------|---------------------------------------------------------------------|
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
| | IN |
- --------------------------------------------------------------------------------
Page 10 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 11 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
|--------|---------------------------------------------------------------------|
| 1 | NAMES OF REPORTING PERSONS |
| | I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
| | |
| | Alan G. Walton |
|--------|---------------------------------------------------------------------|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
| | (SEE INSTRUCTIONS) (a) [ ] |
| | (b) [ ] |
|--------|---------------------------------------------------------------------|
| 3 | SEC USE ONLY |
| | |
|--------|---------------------------------------------------------------------|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |
| | |
| | United States |
|-----------------|--------|---------------------------------------------------|
| | 5 | SOLE VOTING POWER |
| | | 0 Shares |
| NUMBER OF |--------|---------------------------------------------------|
| SHARES | 6 | SHARED VOTING POWER |
| BENEFICIALLY | | 1,750,000 Shares |
| OWNED BY |--------|---------------------------------------------------|
| EACH | 7 | SOLE DISPOSITIVE POWER |
| REPORTING | | 0 Shares |
| PERSON |--------|---------------------------------------------------|
| WITH: | 8 | SHARED DISPOSITIVE POWER |
| | | 1,750,000 Shares |
|------------------------------------------------------------------------------|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| | |
| | 1,750,000 Shares |
|--------|---------------------------------------------------------------------|
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN |
| | SHARES (SEE INSTRUCTIONS) |
| | [ ] |
|--------|---------------------------------------------------------------------|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
| | 7.7% |
|--------|---------------------------------------------------------------------|
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
| | IN |
- --------------------------------------------------------------------------------
Page 11 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 12 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
|--------|---------------------------------------------------------------------|
| 1 | NAMES OF REPORTING PERSONS |
| | I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
| | |
| | Jonathan J. Fleming |
|--------|---------------------------------------------------------------------|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
| | (SEE INSTRUCTIONS) (a) [ ] |
| | (b) [ ] |
|--------|---------------------------------------------------------------------|
| 3 | SEC USE ONLY |
| | |
|--------|---------------------------------------------------------------------|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |
| | |
| | United States |
|-----------------|--------|---------------------------------------------------|
| | 5 | SOLE VOTING POWER |
| | | 0 Shares |
| NUMBER OF |--------|---------------------------------------------------|
| SHARES | 6 | SHARED VOTING POWER |
| BENEFICIALLY | | 1,750,000 Shares |
| OWNED BY |--------|---------------------------------------------------|
| EACH | 7 | SOLE DISPOSITIVE POWER |
| REPORTING | | 0 Shares |
| PERSON |--------|---------------------------------------------------|
| WITH: | 8 | SHARED DISPOSITIVE POWER |
| | | 1,750,000 Shares |
|------------------------------------------------------------------------------|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| | |
| | 1,750,000 Shares |
|--------|---------------------------------------------------------------------|
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN |
| | SHARES (SEE INSTRUCTIONS) |
| | [ ] |
|--------|---------------------------------------------------------------------|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
| | 7.7% |
|--------|---------------------------------------------------------------------|
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
| | IN |
- --------------------------------------------------------------------------------
Page 12 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 13 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
NOTE: This Statement on Schedule 13G is being filed on behalf of (i) Oxford
Bioscience Partners II, L.P., a Delaware limited partnership; (ii) Oxford
Bioscience Partners (Adjunct) II, L.P., a Delaware limited partnership; (iii)
Oxford Bioscience Partners (GS-Adjunct) II, L.P., a Delaware limited
partnership; (iv) OBP Management II, L.P., a Delaware limited partnership; (v)
Oxford Bioscience Partners (Bermuda) II Limited Partnership, a Bermuda limited
partnership; (vi) OBP Management (Bermuda) II Limited Partnership, a Bermuda
limited partnership; (vii) OBP Management (Bermuda) II Ltd., a Bermuda company;
(viii) Edmund M. Olivier; (ix) Cornelius T. Ryan; (x) Alan G. Walton and (xi)
Jonathan J. Fleming.
Item 1(a). Name of Issuer: InKine Pharmaceutical Company, Inc.
--------------
Item 1(b). Address of Issuer's Principal Executive Offices:
-----------------------------------------------
Sentry Park East, 1720 Walton Road, Blue Bell, Pennsylvania 19422
<TABLE>
<CAPTION>
Item 2(a) Item 2(b) Item 2(c)
--------- --------- ---------
Citizenship or Place
Name of Person Filing Address of Organization
--------------------- ------- ---------------
<S> <C> <C>
Oxford Bioscience Partners II, L.P. Oxford Bioscience Partners Delaware
("OBP II") 315 Post Road West
Westport, CT 06880
Oxford Bioscience Partners Oxford Bioscience Partners Delaware
(Adjunct) II, L.P. ("OBP 315 Post Road West
Adjunct II") Westport, CT 06880
Oxford Bioscience Partners Oxford Bioscience Partners Delaware
(GS-Adjunct) II, L.P. ("OBP 315 Post Road West
GS-Adjunct II") Westport, CT 06880
OBP Management II, L.P. ("OBP Oxford Bioscience Partners Delaware
Management II"), the general 315 Post Road West
partner of OBP II, OBP Adjunct Westport, CT 06880
II and OBP GS-Adjunct II
Oxford Bioscience Partners Richmond House Bermuda
(Bermuda) II Limited Par-la-Ville Road
Partnership ("OBP Bermuda II") Hamilton, Bermuda
OBP Management (Bermuda) II Limited Richmond House Bermuda
Partnership ("OBP Management Par-la-Ville Road
Bermuda II"), the general Hamilton, Bermuda
partner of OBP Bermuda II
</TABLE>
Page 13 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 14 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
<TABLE>
<S> <C> <C>
OBP Management (Bermuda) II Ltd. Richmond House Bermuda
("OBP Bermuda II Ltd"), the Par-la-Ville Road
corporate general partner of Hamilton, Bermuda
OBP Management Bermuda II
Edmund M. Olivier, a general Oxford Bioscience Partners United States
partner of OBP Management II 650 Town Center Drive
and OBP Management Bermuda II Costa Mesa, California 92626
Cornelius T. Ryan, a general Oxford Bioscience Partners United States
partner of OBP Management II 315 Post Road West
and OBP Management Bermuda II Westport, CT 06880
Alan G. Walton, a general partner Oxford Bioscience Partners United States
of OBP Management II and OBP 315 Post Road West
Management Bermuda II Westport, CT 06880
Jonathan J. Fleming, a general Oxford Bioscience Partners United States
partner of OBP Management II 31 St. James Avenue, Suite 570
and OBP Management Bermuda II Boston, MA 02116
</TABLE>
Item 2(d). Title of Class of Securities: Common Stock, $.0001 par value.
----------------------------
Item 2(e). CUSIP Number: 457 214 10 4
------------
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or
---------------------------------------------------------
13d-2(b), check whether the person filing is a:
----------------------------------------------
(a) [ ] Broker or Dealer registered under Section 15 of the
Securities Exchange Act of 1934 (the "Act").
(b) [ ] Bank as defined in Section 3(a)(6) of the Act.
(c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act.
(d) [ ] Investment Company registered under Section 8 of the
Investment Company Act of 1940.
(e) [ ] Investment Adviser registered under Section 203 of the
Investment Advisers Act of 1940.
(f) [ ] Employee Benefit Plan, Pension Fund which is subject to the
provisions of the Employee Retirement Income Security Act of
1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F) of the
Act.
(g) [ ] Parent Holding Company, in accordance with Rule
13d-1(b)(ii)(G) of the Act.
(h) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(H) of the
Act.
None of the above.
Page 14 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 15 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
Item 4. Ownership.
---------
(a) Amount Beneficially Owned: As of December 31, 1998, each
of the following is the owner of record of the number of
shares of Common Stock set forth next to his, her or its
name:
<TABLE>
<S> <C>
OBP II: 1,000,335 Shares
OBP Adjunct II: 0 Shares
OBP GS-Adjunct II: 0 Shares
OBP Management II: 0 Shares
OBP Bermuda II: 749,665 Shares
OBP Management Bermuda II: 0 Shares
OBP Bermuda II Ltd: 0 Shares
Mr. Olivier: 0 Shares
Mr. Ryan: 0 Shares
Mr. Walton: 0 Shares
Mr. Fleming: 0 Shares
</TABLE>
By virtue of their relationship as affiliated limited
partnerships, whose sole general partners share individual
general partners, OBP II, OBP Adjunct II, OBP GS-Adjunct II and
OBP Bermuda II may be deemed to share voting power and the power
to direct the disposition of the shares of Common Stock which
each partnership owns of record. Messrs. Ryan, Walton, Olivier
and Fleming are general partners of both OBP Management II, the
general partner of OBP II, and OBP Management Bermuda II, the
general partner of OBP Bermuda II. Therefore, each of Messrs.
Ryan, Walton, Olivier and Fleming may be deemed to own
beneficially the shares held by OBP II and OBP Bermuda II.
(b) Percent of Class:
<TABLE>
<S> <C>
OBP II: 7.7%
OBP Adjunct II: 7.7%
OBP GS-Adjunct II: 7.7%
OBP Management II: 7.7%
OBP Bermuda II: 7.7%
OBP Management Bermuda II: 7.7%
OBP Bermuda II Ltd: 7.7%
Mr. Olivier: 7.7%
Mr. Ryan: 7.7%
Mr. Walton: 7.7%
Mr. Fleming: 7.7%
</TABLE>
The foregoing percentages are calculated based on the 22,703,175
share of Common Stock reported to be outstanding as of November 12,
1998 in the Quarterly Report on Form 10-QSB of InKine Pharmaceutical
Company, Inc. for the quarter ended September 30, 1998, as adjusted
pursuant to Rule 13d-3 (d)(1) of the Act.
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
<TABLE>
<S> <C>
OBP II: 0 Shares
OBP Adjunct II: 0 Shares
OBP GS-Adjunct II: 0 Shares
OBP Management II: 0 Shares
OBP Bermuda II: 0 Shares
OBP Management Bermuda II: 0 Shares
OBP Bermuda II Ltd: 0 Shares
Mr. Olivier: 0 Shares
Mr. Ryan: 0 Shares
</TABLE>
Page 15 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 16 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
<TABLE>
<S> <C>
Mr. Walton: 0 Shares
Mr. Fleming: 0 Shares
</TABLE>
(ii) shared power to vote or to direct the vote:
<TABLE>
<S> <C>
OBP II: 1,750,000 Shares
OBP Adjunct II: 1,750,000 Shares
OBP GS-Adjunct II: 1,750,000 Shares
OBP Management II: 1,750,000 Shares
OBP Bermuda II: 1,750,000 Shares
OBP Management Bermuda II: 1,750,000 Shares
OBP Bermuda II Ltd: 1,750,000 Shares
Mr. Olivier: 1,750,000 Shares
Mr. Ryan: 1,750,000 Shares
Mr. Walton: 1,750,000 Shares
Mr. Fleming: 1,750,000 Shares
</TABLE>
(iii) sole power to dispose or to direct the disposition of:
<TABLE>
<S> <C>
OBP II: 0 Shares
OBP Adjunct II: 0 Shares
OBP GS-Adjunct II: 0 Shares
OBP Management II: 0 Shares
OBP Bermuda II: 0 Shares
OBP Management Bermuda II: 0 Shares
OBP Bermuda II Ltd: 0 Shares
Mr. Olivier: 0 Shares
Mr. Ryan: 0 Shares
Mr. Walton: 0 Shares
Mr. Fleming: 0 Shares
</TABLE>
(iv) shared power to dispose or to direct the disposition of:
<TABLE>
<S> <C>
OBP II: 1,750,000 Shares
OBP Adjunct II: 1,750,000 Shares
OBP GS-Adjunct II: 1,750,000 Shares
OBP Management II: 1,750,000 Shares
OBP Bermuda II: 1,750,000 Shares
OBP Management Bermuda II: 1,750,000 Shares
OBP Bermuda II Ltd: 1,750,000 Shares
Mr. Olivier: 1,750,000 Shares
Mr. Ryan: 1,750,000 Shares
Mr. Walton: 1,750,000 Shares
Mr. Fleming: 1,750,000 Shares
</TABLE>
Each of OBP II, OBP Adjunct II, OBP GS-Adjunct II, OBP Management
II, OBP Bermuda II, OBP Management Bermuda II, OBP Bermuda II Ltd,
Mr. Olivier, Mr. Ryan, Mr. Walton and Mr. Fleming expressly
disclaims beneficial ownership of any shares of Common Stock of
InKine Pharmaceutical Company, Inc., except any shares held directly
of record.
Item 5. Ownership of Five Percent or Less of a Class.
Page 16 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 17 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check
the following: [ ]
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
---------------------------------------------------------------
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired
------------------------------------------------------------------
the Security Being Reported on by the Parent Holding Company.
------------------------------------------------------------
Not applicable.
Item 8. Identification and Classification of Members of the Group.
---------------------------------------------------------
Not applicable. OBP II, OBP Adjunct II, OBP GS-Adjunct II, OBP
Bermuda II, OBP Management Bermuda II, OBP Bermuda II Ltd, Mr.
Olivier, Mr. Ryan, Mr. Walton and Mr. Fleming expressly disclaim
membership in a "group" as defined in Rule 13d-1(b)(ii)(H) of the
Act.
Item 9. Notice of Dissolution of Group.
------------------------------
Not applicable.
Item 10. Certification.
-------------
Not applicable. This statement on Schedule 13G is not filed pursuant
to Rule 13d-1(b) or Rule 13d-1(c).
Page 17 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 18 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
Signature
---------
After reasonable inquiry and to the best of his, her or its knowledge
and belief, each of the undersigned certifies that the information set forth in
this statement is true, complete and correct.
Dated: February 12, 1999
OXFORD BIOSCIENCE PARTNERS II L.P.
By: OBP Management II L.P., its general partner
By: *
--------------------------------------------
Jonathan J. Fleming
General Partner
OXFORD BIOSCIENCE PARTNERS (ADJUNCT) II, L.P.
By: OBP Management II, L.P., its general partner
By: *
--------------------------------------------
Jonathan J. Fleming
General Partner
OXFORD BIOSCIENCE PARTNERS
(GS - ADJUNCT) II, L.P.
By: OBP Management II, L.P., its general partner
By: *
--------------------------------------------
Jonathan J. Fleming
General Partner
OXFORD BIOSCIENCE MANAGEMENT PARTNERS II
By: *
--------------------------------------------
Jonathan J. Fleming
General Partner
OXFORD BIOSCIENCE PARTNERS (BERMUDA) II
LIMITED PARTNERSHIP
By: OBP Management (Bermuda) II Limited Partnership,
its general partner
By: *
--------------------------------------------
Jonathan J. Fleming
General Partner
OBP MANAGEMENT (BERMUDA) II LIMITED PARTNERSHIP
By: OBP Management (Bermuda) II Ltd.,
its general partner
Page 18 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 19 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
By: *
--------------------------------------------
Jonathan J. Fleming
Director
OBP MANAGEMENT (BERMUDA) II LTD.
By: *
Jonathan J. Fleming
Director
*
--------------------------------------------
Cornelius T. Ryan
*
--------------------------------------------
Alan G. Walton
*
--------------------------------------------
Edmund M. Olivier
*
--------------------------------------------
Jonathan J. Fleming
*
--------------------------------------------
Jeffrey M. Held
Attorney-in-Fact
This Schedule 13G was executed by Jeffrey M. Held pursuant to the Power
of Attorney filed with the Securities and Exchange Commission herewith as
Exhibit 2.
Page 19 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 20 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
Exhibit 1
AGREEMENT
Pursuant to Rule 13-d1(f)(1) under the Securities Exchange Act of 1934,
the undersigned hereby agree that only one statement containing the information
required by Schedule 13G need be filed with respect to the ownership by each of
the undersigned of shares of Common Stock of InKine Pharmaceutical Company, Inc.
Dated: February 7, 1999
OXFORD BIOSCIENCE PARTNERS II L.P.
By: OBP Management II L.P., its general partner
By: /s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
General Partner
OXFORD BIOSCIENCE PARTNERS (ADJUNCT) II, L.P.
By: OBP Management II, L.P., its general partner
By: /s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
General Partner
OXFORD BIOSCIENCE PARTNERS
(GS - ADJUNCT) II, L.P.
By: OBP Management II, L.P., its general partner
By: /s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
General Partner
OXFORD BIOSCIENCE MANAGEMENT PARTNERS II
By: /s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
General Partner
OXFORD BIOSCIENCE PARTNERS (BERMUDA) II
LIMITED PARTNERSHIP
By: OBP Management (Bermuda) II Limited Partnership,
its general partner
By: /s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
General Partner
OBP MANAGEMENT (BERMUDA) II LIMITED PARTNERSHIP
By: OBP Management (Bermuda) II Ltd., its general partner
Page 20 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 21 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
By: /s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
Director
OBP MANAGEMENT (BERMUDA) II LTD.
By: /s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
Director
/s/ Cornelius T. Ryan
--------------------------------------------
Cornelius T. Ryan
/s/ Alan G. Walton
--------------------------------------------
Alan G. Walton
/s/ Edmund M. Olivier
--------------------------------------------
Edmund M. Olivier
/s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
Page 21 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 22 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
Exhibit 2
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that the person whose signature appears
below hereby constitutes and appoints Raymond N. Charest, Jeffrey M. Held, and
Amy B. Rensko, and any one of them acting singly, the true and lawful
attorneys-in-fact and agents, with full power of substitution and
resubstitution, for the undersigned and in the undersigned's name, place and
stead, in any and all capacities (until revoked in writing) to sign any and all
instruments, certificates and documents required to be executed on behalf of the
undersigned as an individual or on behalf of the undersigned's holding company,
as the case may be, pursuant to sections 13 and 16 of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), and any and all regulations
promulgated thereunder, and to file the same, with all exhibits thereto, and any
other documents in connection therewith, with the Securities and Exchange
Commission, and with any other entity when and if such is mandated by the
Exchange Act or by the By-laws of the National Association of Securities
Dealers, Inc. granting unto said attorneys-in-fact and agents full power and
authority to do and perform each and every act and thing requisite and necessary
fully to all intents and purposes as the undersigned might or could do in person
thereby ratifying and confirming all that said attorneys-in-fact and agents, or
their substitute or substitutes, may lawfully do or cause to be done by virtue
hereof. Notwithstanding the foregoing, this Power of Attorney shall expire
automatically upon the cessation of the undersigned's reporting obligations
pursuant to sections 13 and 16 of the Exchange Act or on the date that each
attorney-in-fact is no longer employed in their current capacities.
(REMAINDER OF PAGE LEFT INTENTIONALLY BLANK)
Page 22 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 23 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 7th day
of February, 1999.
OXFORD BIOSCIENCE PARTNERS L.P.
By: OBP Management L.P., its general partner
By: /s/ Cornelius T. Ryan
--------------------------------------------
Cornelius T. Ryan
General Partner
OXFORD BIOSCIENCE PARTNERS (BERMUDA) LIMITED PARTNERSHIP
By: OBP Management (Bermuda) Limited Partnership,
its general partner
By: /s/ Cornelius T. Ryan
--------------------------------------------
Cornelius T. Ryan
General Partner
OBP MANAGEMENT L.P.
By: /s/ Cornelius T. Ryan
--------------------------------------------
Cornelius T. Ryan
General Partner
OBP MANAGEMENT (BERMUDA) LTD.
By: /s/ Edmund M. Olivier
--------------------------------------------
Edmund M. Olivier
Director
OBP MANAGEMENT (BERMUDA) LIMITED PARTNERSHIP
By: /s/ Cornelius T. Ryan
--------------------------------------------
Cornelius T. Ryan
General Partner
OXFORD BIOSCIENCE PARTNERS (ADJUNCT), L.P.
By: OBP Management, L.P., its general partner
By: /s/ Cornelius T. Ryan
--------------------------------------------
Cornelius T. Ryan
General Partner
OXFORD BIOSCIENCE MANAGEMENT PARTNERS II
By: /s/ Cornelius T. Ryan
--------------------------------------------
Cornelius T. Ryan
General Partner
Page 23 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 24 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
OXFORD BIOSCIENCE PARTNERS II L.P.
By: OBP Management II L.P., its general partner
By: /s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
General Partner
OXFORD BIOSCIENCE PARTNERS (BERMUDA) II
LIMITED PARTNERSHIP
By: OBP Management (Bermuda) II Limited Partnership, its
general partner
By: /s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
General Partner
OBP MANAGEMENT II, L.P.
By: /s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
General Partner
OBP MANAGEMENT (BERMUDA) II LIMITED PARTNERSHIP
By: OBP Management (Bermuda) II Ltd., its general partner
By: /s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
Director
OXFORD BIOSCIENCE PARTNERS (ADJUNCT) II, L.P.
By: OBP Management II, L.P., its general partner
By: /s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
General Partner
OBP MANAGEMENT (BERMUDA) II LTD.
By: /s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
Director
Page 24 of 25 pages
<PAGE>
- ---------------------------------- ---------------------------
|CUSIP NO. 457214 10 4 | 13G | Page 25 of 25 Pages |
| ----------- | | --- --- |
- ---------------------------------- ---------------------------
OXFORD BIOSCIENCE PARTNERS
(GS - ADJUNCT) II, L.P.
By: OBP Management II, L.P., its general partner
By: /s/ Jonathan J. Fleming
--------------------------------------------
Jonathan J. Fleming
General Partner
/s/ Cornelius T. Ryan
------------------------------------------------
Cornelius T. Ryan
/s/ Alan G. Walton
------------------------------------------------
Alan G. Walton
/s/ Edmund M. Olivier
------------------------------------------------
Edmund M. Olivier
/s/ Jonathan J. Fleming
------------------------------------------------
Jonathan J. Fleming
Page 25 of 25 pages
